Bausch Health Companies Inc
Produces and distributes pharmaceuticals.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Bausch Health's stock, expecting it to rise to $10 in value.
Financial Health
Bausch Health is performing well with strong revenue and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BHC
Pharmaceutical Policy Shift Explained | Pricing Models
The Trump administration's recent drug pricing agreements with major pharmaceutical companies like AstraZeneca and Pfizer aim to lower U.S. drug costs by tying them to international prices. This creates a potential investment opportunity in pharmaceutical firms with strong domestic production and those in the healthcare supply chain that can adapt to the new pricing landscape.
Published: October 12, 2025
Explore BasketWalgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketNavigating U.S. Drug Price Reforms
The White House is demanding major pharmaceutical companies slash U.S. drug prices, creating significant market volatility and threatening industry profits. This creates a potential opening for companies that offer cost-saving alternatives, such as generic drug makers and healthcare service providers.
Published: August 5, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Revenue & Brands
Established prescription and consumer brands drive sales, while new launches and patent expiries shape growth — though revenues can fluctuate with market and competitive pressures.
Balance Sheet Focus
Leverage and debt reduction are important for valuation; successful deleveraging could improve prospects, but indebtedness and legal costs remain material risks.
Global Footprint
A presence across developed and emerging markets offers diversification and growth potential, yet it also brings currency, regulatory and pricing challenges.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
